concept

ERK1/2

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about ERK1/2: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

435Connections

1Hypotheses

1Analyses

50Outgoing

50Incoming

0Experiments

1Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	ERK1/2
Key Genes/Proteins	6-OHDA, Actin, ADAM17, ADRA2A, ADRA2B, AGING
Related Diseases	Aging, Als, ALS, Alzheimer
Linked Hypotheses	1 hypotheses

Pathway Diagram

graph TD
    ERK1_2["ERK1/2"]
    style ERK1_2 fill:#1a237e,stroke:#4fc3f7,stroke-width:3px
    ERK1_2 -->|"interacts"| HSPA1A([HSPA1A])
    ERK1_2 -->|"mediates"| Apoptosis["Apoptosis"]
    ERK1_2 -->|"regulates"| Inflammation["Inflammation"]
    ERK1_2 -->|"mediates"| Astrocyte_Activation["Astrocyte Activation"]
    ERK1_2 -->|"mediates"| Microglia_Activation["Microglia Activation"]
    ERK1_2 -->|"regulates"| neurodegeneration["neurodegeneration"]
    ERK1_2 -->|"regulates"| ADAM17([ADAM17])
    ERK1_2 -->|"activates"| Aging["Aging"]
    ERK1_2 -->|"interacts"| Cancer["Cancer"]
    PRDX1([PRDX1]) -->|"phosphorylates"| ERK1_2
    TGN_020{"TGN-020"} -.->|"inhibits"| ERK1_2
    AKT([AKT]) -.->|"inhibits"| ERK1_2
    oxidative_stress(oxidative stress) -->|"regulates"| ERK1_2
    LL37([LL37]) -->|"interacts"| ERK1_2
    U0126{"U0126"} -.->|"inhibits"| ERK1_2
    CaMKII([CaMKII]) -->|"activates"| ERK1_2
    ADRA2B([ADRA2B]) -->|"activates"| ERK1_2
    SEMA3F([SEMA3F]) -.->|"downregulates"| ERK1_2
    AGING([AGING]) -->|"activates"| ERK1_2

Outgoing (279)

Target	Relation	Type	Str
HSPA1A	interacts_with	gene	0.90
Apoptosis	mediates	process	0.88
Inflammation	regulates	process	0.85
APOPTOSIS	associated_with	process	0.85
Apoptosis	regulates	process	0.85
Apoptosis	associated_with	process	0.80
Microglia Activation	mediates	process	0.78
Astrocyte Activation	mediates	process	0.78
neurodegeneration	regulates	process	0.70
ADAM17	regulates	gene	0.70
Alzheimer	activates	disease	0.65
Als	activates	disease	0.65
Multiple Sclerosis	activates	disease	0.65
Senescence	activates	disease	0.65
Ischemia	associated_with	disease	0.65
Aging	activates	disease	0.65
Encephalitis	associated_with	disease	0.65
Multiple Sclerosis	associated_with	disease	0.65
Neuroinflammation	activates	disease	0.65
Parkinson	inhibits	disease	0.65
Fibrosis	activates	disease	0.65
Als	inhibits	disease	0.65
Aging	inhibits	disease	0.65
Alzheimer	protects_against	disease	0.65
Als	regulates	disease	0.65
Glioblastoma	regulates	disease	0.65
Cancer	inhibits	disease	0.65
Neuropathy	transports	disease	0.65
Neurodegeneration	therapeutic_target	disease	0.65
Cancer	interacts_with	disease	0.65
Stroke	activates	disease	0.65
ALS	activates	disease	0.65
Ischemia	activates	disease	0.65
Parkinson	activates	disease	0.65
Alzheimer	inhibits	disease	0.65
Als	therapeutic_target	disease	0.65
Cancer	therapeutic_target	disease	0.65
Cancer	activates	disease	0.65
Stroke	inhibits	disease	0.65
Depression	activates	disease	0.65
Neurodegeneration	activates	disease	0.65
Inflammation	associated_with	disease	0.65
Tumor	activates	disease	0.65
Alzheimer	therapeutic_target	disease	0.65
AQP4	inhibits	gene	0.60
MICROGLIA	activates	gene	0.60
GFAP	inhibits	gene	0.60
Microglia	activates	cell_type	0.60
Astrocyte	activates	cell_type	0.60
Neurogenesis	activates	pathway	0.60

Incoming (156)

Source	Relation	Type	Str
GPR32	activates	protein	0.85
PRDX1	phosphorylates	protein	0.85
AKT	inhibits	gene	0.80
FGF21	activates	gene	0.80
TGN-020	inhibits	drug	0.80
LL37	interacts_with	protein	0.75
oxidative stress	regulates	phenotype	0.75
U0126	inhibits	drug	0.72
ADRA2B	activates	gene	0.70
SEMA3F	downregulates	gene	0.70
MT1 receptor	regulates	protein	0.70
CaMKII	activates	protein	0.70
oxidative stress	modulates	process	0.70
NGF	activates	gene	0.60
TLR4	activates	gene	0.60
APP	activates	gene	0.60
C-JUN	activates	gene	0.60
BDNF	activates	gene	0.60
IGF-1	activates	gene	0.60
APOE	activates	gene	0.60
MTOR	activates	gene	0.60
ERK	therapeutic_target	gene	0.60
ALZHEIMER	therapeutic_target	gene	0.60
OCT4	activates	gene	0.60
NANOG	activates	gene	0.60
PERK	activates	gene	0.60
REELIN	activates	gene	0.60
APOER2	activates	gene	0.60
SRC	activates	gene	0.60
HTT	activates	gene	0.60
SYT4	activates	gene	0.60
HUNTINGTIN	activates	gene	0.60
FYN	associated_with	gene	0.60
ATP	activates	gene	0.60
ASC	activates	gene	0.60
COMPLEMENT	activates	gene	0.60
NLRP3	activates	gene	0.60
P2X7	activates	gene	0.60
AKT	regulates	gene	0.60
MYD88	associated_with	gene	0.60
TREM2	activates	gene	0.60
IL-10	activates	gene	0.60
AKT	activates	gene	0.60
NEURODEGENERATION	activates	gene	0.60
ROS	activates	gene	0.60
APOPTOSIS	activates	gene	0.60
AMPK	activates	gene	0.60
NRF2	activates	gene	0.60
ALZHEIMER	activates	gene	0.60
CREB	activates	gene	0.60

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Gamma entrainment suppresses hippocampal ERK1/2 hyperactivit	0.711	alzheimers	Gamma entrainment therapy to restore hip

Mentioning Analyses (1)

Scientific analyses that reference this entity

What is the optimal dosage and timing of melatonin administration for AD prevent

neurodegeneration | 2026-04-26 | 7 hypotheses Top: 0.735

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (1)

Multi-agent debates referencing this entity

What is the optimal dosage and timing of melatonin administration for AD prevent

closed · Rounds: 4 · Score: 1.00 · 2026-04-26

Related Research

Hypotheses and analyses mentioning ERK1/2 in their description or question text

No additional research found